Loading clinical trials...
Loading clinical trials...
An Open-label, Multi-center, Phase I Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IBR733 Cell Injection in Acute Myeloid Leukemia
Conditions
Interventions
IBR733 Cell Injection
Locations
1
China
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Start Date
February 1, 2024
Primary Completion Date
February 1, 2025
Completion Date
August 1, 2025
Last Updated
January 31, 2024
NCT06285890
NCT06220162
NCT04065399
NCT06484062
NCT04628026
NCT06994676
Lead Sponsor
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions